Earnings Call
Jul 23, 2026
Q2 FY2026
EPS Estimate
2.08
EPS Actual
2.37
Post-Earnings Close
$355.48
Earnings Reaction
-0.8%
West Pharmaceutical Services delivered a standout second quarter, with revenues of $872 million growing 12.7% organically and adjusted EPS of $2.37, both materially ahead of expectations and representing 29% earnings growth year-over-year. The beat was broad-based but concentrated in the Proprietary Products segment, where HVP Components, now nearly half of total company revenues at $424 million, grew 18.4% organically. Critically, the outperformance was not solely a GLP-1 story: non-GLP-1 HVP Components accelerated to high-teens organic growth, driven by Biologics and Biosimilars demand and an expanding Annex 1 upgrade cycle, and this was the largest contributor to the quarter's upside surprise.
Report generated on Jul 24, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full WST analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.